Anavex Life Sciences

Anavex has filed final proxy materials for the September 24 annual meeting and is urging shareholders to support its six nominees for the board of directors after entering a proxy fight with PVG Asset Management. Shareholders of record as of July 31, 2026, are eligible to vote; if elected, half of the board would have been replaced since the start of the year. The biopharma company named Dr. Terrie Kellmeyer as interim CEO, filed an IND application for an Alzheimer’s treatment, and is conducting two clinical pharmacology studies. In May Anavex received a Nasdaq deficiency notice for a late 10‑Q filing and has submitted a compliance plan; PVG and Patrick Adams together hold 0.35% of the outstanding shares. » More on de.investing.com

Anavex Life Sciences missed timely filing of the quarterly report (Form 10-Q) for the quarter ended March 31, 2026, thereby violating NASDAQ listing rule 5250(c)(1). NASDAQ set a deadline of July 20, 2026 to submit a plan to regain compliance. The stock last fell 6.9% to $2.71 and trades near its 52-week low; Anavex is working to complete and file the report. The notice has no immediate effect on the listing of the common stock. » More on de.investing.com

Anavex publishes findings that shared disturbances of autophagy constitute a molecular link between autism spectrum disorders and Alzheimer’s disease. The oral drug candidate blarcamesin activates SIGMAR1 and is intended to restore autophagic processes; earlier studies and completed clinical trials suggested improvement in autophagic flux and a slowing of cognitive decline in early Alzheimer’s. The stock trades near its 52-week low, but analysts see price targets between $20 and $24, and the balance sheet shows more cash than debt, supporting the continuation of the clinical programs. » More on de.investing.com